Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision updated from v3.6.4 to v3.6.5 on the page, indicating a new published revision. This reflects a maintenance/version update rather than a substantive change to the page's content.SummaryDifference0.0%

- Check15 days agoChange DetectedPlain Language Summary has been removed from the page, removing a lay-friendly overview of the trial. Readers will need to consult the more technical sections for study details.SummaryDifference0.0%

- Check22 days agoChange DetectedThe page revision label changed from v3.6.3 to v3.6.4, indicating a new build/version of the page.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page revision was updated from v3.6.0 to v3.6.3. This reflects a minor update to the page metadata rather than the study content.SummaryDifference0.0%

- Check65 days agoChange DetectedThe page now indicates the trial is no longer recruiting and adds user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention/Treatment heading formatting is adjusted and the revision note updated from v3.5.5 to v3.6.0.SummaryDifference0.3%

- Check72 days agoChange DetectedNew revision history entries were added for 2026-06-01 and 2026-05-28 with Revision: v3.5.5, and older revision entries (2026-05-26, 2026-05-27) along with Revision: v3.5.4 were removed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.